BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 19463426)

  • 1. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial.
    Tamburino C; La Manna A; Di Salvo ME; Sacchetta G; Capodanno D; Mehran R; Dangas G; Corcos T; Prati F
    JACC Cardiovasc Interv; 2009 Mar; 2(3):197-204. PubMed ID: 19463426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design.
    Tamburino C; Capodanno D; La Manna A; di Salvo M; Sanfilippo A; Prati F
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):53-8. PubMed ID: 19829136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical coherence tomographic results at six-month follow-up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial).
    La Manna A; Capodanno D; Cera M; Di Salvo ME; Sacchetta G; Corcos T; Prati F; Tamburino C
    Am J Cardiol; 2009 Jun; 103(11):1551-5. PubMed ID: 19463514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry.
    Tamburino C; Capodanno D; Di Salvo ME; Sanfilippo A; Cascone I; Incardona V; Longo G; Giacoppo D; Capranzano P; Sgroi C; Ussia G; Monaco A; La Manna A
    EuroIntervention; 2012 Jan; 7(9):1062-8. PubMed ID: 22207230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
    Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE
    JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and mid-term clinical outcomes with the CATANIA coronary stent system vs. bare metal stents in patients with coronary artery disease.
    Capodanno D; La Manna A; Di Salvo ME; Sanfilippo A; Corcos T; Tamburino C
    Cardiovasc Revasc Med; 2009; 10(4):216-20. PubMed ID: 19815167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System.
    Cutlip DE; Garratt KN; Novack V; Barakat M; Meraj P; Maillard L; Erglis A; Jauhar R; Popma JJ; Stoler R; Silber S;
    JACC Cardiovasc Interv; 2017 Jan; 10(2):160-167. PubMed ID: 28104210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
    Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
    JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial.
    Qian J; Xu B; Lansky AJ; Yang YJ; Qiao SB; Wu YJ; Chen J; Hu FH; Yang WX; Mintz GS; Leon MB; Gao RL
    Chin Med J (Engl); 2012 Mar; 125(6):970-6. PubMed ID: 22613516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results.
    Ormiston JA; Webster MW; Schwartz RS; Gladding P; Stewart JT; Kay IP; Ruygrok PN; Hatrick R
    JACC Cardiovasc Interv; 2009 Oct; 2(10):1017-24. PubMed ID: 19850264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial.
    Park SD; Yoon CH; Oh IY; Suh JW; Cho YS; Youn TJ; Choi DJ; Chae IH
    Trials; 2013 Feb; 14():38. PubMed ID: 23394404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.